Macrocyclics is categorized under Commercial Biotechnical Research in Dallas, TX and active since 2011.
Macrocyclics was established in 2011, and today employs 1 to 4, earning $10.000.000 to $19.9999.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 3259980 by the NAICS.
If you are seeking more information, feel free to contact Dean Sherry, President at the company’s branch by writing to 1309 Record Crossing Road, Dallas, Texas TX 75235 or by phoning (972) 250-2248. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Macrocyclics |
| Contact Person: | Dean Sherry, President |
| Address: | 1309 Record Crossing Road, Dallas, Texas 75235 |
| Phone Number: | (972) 250-2248 |
| Website Address: | areva.com |
| Annual Revenue (USD): | $10.000.000 to $19.9999.999 |
| Founded: | 2011 |
| Location Type: | Branch |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 3259980 |
| Share This Business: |
Macrocyclics was started in 2011 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 3259980. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $10.000.000 to $19.9999.999 per annum.
Feel free to contact Dean Sherry, President for inquiries that concern Macrocyclics by calling the company number (972) 250-2248, as your correspondence is most welcome. Additionally, the physical location of the branch of Macrocyclics can be found at the coordinates 32.8168,-96.85779 as well as the street address 1309 Record Crossing Road in Dallas, Texas 75235.
For its online presence, you may visit Macrocyclics’s website at areva.com and engage with its social media outlets through on Twitter and on Facebook.